Document is current
Any future updates will be listed below
-
Authors
Veritti, Daniele https://orcid.org/0000-0003-0148-5348
Sarao, Valentina https://orcid.org/0000-0003-0041-5073
Gonfiantini, Marco https://orcid.org/0009-0009-1580-7118
Rubinato, Leopoldo https://orcid.org/0009-0003-0607-6516
Lanzetta, Paolo https://orcid.org/0000-0003-3746-141X
- License Information
-
More Information
Article History
Received: 23 February 2024
Accepted: 17 July 2024
First Online: 9 August 2024
Declarations
:
: Daniele Veritti is consultant for Bayer, Novartis, and Roche. Valentina Sarao is consultant for Bayer, I-Care, and Roche. Marco Gonfiantini and Leopoldo Rubinato declare that they have no competing interests. Paolo Lanzetta is consultant for Aerie, Allergan, Apellis, Bausch & Lomb, Bayer, Biogen, Boehringer Ingelheim, I-Care, Genentech, Novartis, Ocular Therapeutix, Outlook Therapeutics, and Roche.
: This study was approved by the IEMO institutional review board (reference number: 2024.0430/f) and adhered to the tenets of the Declaration of Helsinki. Informed consent was obtained from all patients for both the participation in the study and the publication of the results.
